Antibody-suppressor CXCR5+CD8+ T cellular therapy ameliorates antibody-mediated rejection following kidney transplant in CCR5 KO mice

• DOI: 10.1111/ajt.16988
• Publication Date: 2022-02-03T17:43:48Z
• Authors: Jason M. Zimmerer; Jing L. Han; Chelsea M. Peterson; Qiang Zeng; Bryce A. Ringwald; Clarissa Cassol; Sachi Chaudhari; Madison Hart; Jessica Hemminger; Anjali Satoskar; Mahmoud Abdel-Rasoul; Jiao-Jing Wang; Robert T. Warren; Zheng J. Zhang; Christopher K. Br...; Ginny L. Bumgardner
• Keywords: CXCR5; Donor-Specific Antibodies

CCR5 KO kidney transplant (KTx) recipients are extraordinarily high alloantibody producers and develop pathology that mimics human antibody-mediated rejection (AMR). C57BL/6 mice (H-2b) were transplanted with A/J kidneys (H-2a); select cohorts received adoptive cell therapy (ACT) alloprimed CXCR5+CD8+ T cells (or control cells) on day 5 after KTx. ACT efficacy was evaluated by measuring posttransplant alloantibody, pathology, allograft survival. Recipients assessed for the quantity of CD8-mediated cytotoxicity to IgG+ B cells. Alloantibody titer in four-fold higher than recipients. The proportion 7 days KTx peripheral blood, lymph node, spleen substantially lower compared In vivo towards also reduced six-fold (but not CXCR5−CD8+ or third-party primed titer, ameliorated AMR prolonged These results indicate a deficiency function contributes recipient mice, which can be rescued ACT.